Physician profile
Frederick A Rowe
NPI 1215927405
$9,593.75
in general payments reported to CMS, 2019-2025
29 companies · $57.33 in 2025
The $57.33 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,409 · 2020: $1,309 · 2021: $2,156 · 2022: $1,857 · 2023: $1,946 · 2024: $860 · 2025: $57.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,841 · Education: $22.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,840.94 |
| Education | $22.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,981.22 | 2019-2024 | Xifaxan, Trulance |
| Abbvie INC. | $2,134.47 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $938.81 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $739.98 | 2019-2024 | Entyvio |
| Merck Sharp & Dohme LLC | $457.95 | 2019-2024 | Dificid |
| Pfizer INC. | $349.26 | 2019-2024 | |
| Genzyme Corporation | $199.91 | 2022-2023 | |
| Ardelyx, INC. | $164.29 | 2022-2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $160.84 | 2022-2024 | Dupixent |
| Allergan, INC. | $152.31 | 2019-2020 | |
| Vivus LLC | $145.35 | 2019-2020 | |
| Daiichi Sankyo INC. | $118.57 | 2019-2023 | Injectafer |
| Ironwood Pharmaceuticals, INC | $106.09 | 2019-2024 | Linzess |
| Celgene Corporation | $97.18 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $96.04 | 2020-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $89.89 | 2019-2023 | |
| Braintree Laboratories, INC. | $89.45 | 2020-2024 | Suflave |
| Intercept Pharmaceuticals, INC. | $89.22 | 2020-2023 | Ocaliva |
| Ethicon US, LLC | $66.67 | 2020 | |
| Ferring Pharmaceuticals INC. | $65.80 | 2019-2023 | Rebyota |
| Acell, INC. | $58.82 | 2019 | |
| Ucb, INC. | $48.92 | 2019 | |
| Shionogi INC | $47.42 | 2019 | |
| Qol Medical, LLC | $45.24 | 2020 | |
| Endo Pharmaceuticals INC. | $36.91 | 2019 | |
| Phathom Pharmaceuticals, INC. | $32.60 | 2024 | Voquezna |
| Lilly USA, LLC | $29.81 | 2024 | Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.53 | 2024 | Cyltezo |
| Celltrion USA INC. | $22.20 | 2024 | Zymfentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Rowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.